Home
GSC Biological and Pharmaceutical Sciences
Peer-reviewed Journal | Impact factor 8.1 | ISSN: 2581-3250 | CAS Source Indexed | Crossref DOI

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

Research and review articles are invited for publication in September 2026 - Vol. 36, Issue 3 

🌟 GSC Biological and Pharmaceutical Sciences (GSCBPS) 🌟

Low Publication Charges | Fast Editorial Processing | Crossref DOI Linking | Transparent Peer-Review Process

Publishing quality research in Biological Sciences, Pharmaceutical Sciences, Medicine, Healthcare and Allied Life Sciences.

e-ISSN: 2581-3250 | Impact Factor: 8.1 | Established: 2017 | Charges: USD 35 / INR 2100

📄 Submit Manuscript 👉 Author Guidelines 📚 Published Articles 

cfDNA and associated risk factors in the early diagnosis of cancers in Côte d’Ivoire: The case of primary liver cancer related to viral hepatitis B

Breadcrumb

  • Home
  • CfDNA and Associated Risk Factors In The Early Diagnosis of Cancers In Côte D’Ivoire: The Case of Primary Liver Cancer Related To Viral Hepatitis B
  • cfDNA and associated risk factors in the early diagnosis of cancers in Côte d’Ivoire: The case of primary liver cancer related to viral hepatitis B

Moussa Doumbia 1, *, Bakary Coulibaly 2, Daouda Sevede 1, Viviane Akissi Kouakou 1, Pascal Pineau 3 and Mireille Dosso 1

1 Department of Bacteriology and Virology, Pasteur Institut of Côte d'Ivoire.
2 Agrovalorisation laboratory, Department of Biochemistry-Microbiology, UFR Agroforestry, Jean Lorougnon Guédé University, Daloa, Côte d'Ivoire.
3 "Nuclear Organisation and Oncogenesis" Unit, INSERM U993, Institut Pasteur, Paris, France.
Research Article
GSC Biological and Pharmaceutical Sciences, 2023, 24(03), 302–308.
Article DOI: 10.30574/gscbps.2023.24.3.0379
DOI url: https://doi.org/10.30574/gscbps.2023.24.3.0379
Received on 02 August 2023; revised on 18 September 2023; accepted on 21 September 2023
Introduction: In Côte d'Ivoire (CI), according to Globocan 2020 primary liver cancer (PLC) had an incidence of 10.1/1.0E+05 inhabitants in men (2nd rank) and 5.5/1.0E+05 inhabitants among women (4th rank). This situation has so far been favored by late diagnosis and ignorance of the risk factors responsible for the tumor in people at risk.
Objective: To detect free circulating DNA (cfDNA) and evaluate its possible diagnostic role in order to contribute to the prevention of PLC in CI.
Methodology: Prospective experimental study carried out at the Institut Pasteur in CI in patients coming for alfa-fetoprotein assay. Sociodemographic, clinical, paraclinical and epidemiological data were collected. A blood sample was taken for biological analysis. Data collected in Excel and processed with the GraphPad Prism 5.
Results: 142 predominantly male patients with an average age of 45 were included. More than 50% had the same dietary habits including the consumption of tap water, rice, cassava, plantain, millet, maize and yam and 18% regularly consumed alcohol. 66.66% were carriers of chronic viral hepatitis B (HVB) including 2.81% at the cirrhosis stage and 0.70% at the PLC stage. 20% had a history of familial hepatitis and 9.6% a notion of familial cancer. The cfDNA concentration ranged from 38ng/ml to 10763ng/ml for an average of 571ng/ml. The elevation of AFP and transaminase levels was related to the presence of HBsAg (P˂0.001; P=0.02). In addition, the concentration of cDNA was strongly linked to HBsAg carriage as well as to other factors including the notion of familial cancer (P=0.03), and consumption of alcohol (p =0.04) and/or tobacco (p=0.02). Conclusion: HVB remains the predominant risk factor that can lead to PLC. The dosage of cfDNA and the monitoring of food and life hygiene in a chronic carrier of HVB could contribute to the prevention of PLC in the latter.
HBsAg; CIDNA; Risk factors; Liver cancer
https://gscbps.gsconlinepress.com/sites/default/files/fulltext_pdf/GSCBPS-2023-…

Preview Article PDF

Moussa Doumbia, Bakary Coulibaly, Daouda Sevede, Viviane Akissi Kouakou, Pascal Pineau and Mireille Dosso. cfDNA and associated risk factors in the early diagnosis of cancers in Côte d’Ivoire: The case of primary liver cancer related to viral hepatitis B. GSC Biological and Pharmaceutical Sciences, 2023, 24(3), 302-308. Article DOI: https://doi.org/10.30574/gscbps.2023.24.3.0379


📝 Copyright, Licensing and Permissions: © Copyright Author(s). This article is published under the 🌐 Creative Commons Attribution 4.0 International License (CC BY 4.0) , which permits unrestricted use, distribution, adaptation, and reproduction in any medium, provided the original author(s) and source are properly credited, a link to the license is provided, and any changes made are indicated.


⚠️ Disclaimer: The statements, opinions, interpretations, and data presented in this publication are solely those of the individual author(s). GSC Biological and Pharmaceutical Sciences (GSCBPS), the editors, reviewers, editorial board, and publisher disclaim responsibility for any errors, omissions, or consequences arising from the use of the information contained in this article.


🏆 Get Publication Certificate 📄 Download Letter of Acceptance 🔗 Verify Crossref DOI 📘 View Issue Cover Page 👨‍🔬 Editorial Board 📑 Table of Contents 

🚀 Publish Your Research in International Peer Reviewed Open Access Journal - GSC Biological and Pharmaceutical Sciences (GSCBPS)

Submit your manuscripts from Biological Sciences, Pharmaceutical Sciences, Medicine, Healthcare, Biotechnology and Allied Life Sciences etc.

🌍 International Journal   |   👨‍🔬 Transparent Peer Review Process   |   🌐 Open Access Publishing   |   🔗 Crossref DOI 
⚡ Fast Editorial Processing   |   💰 Low Publication Charges

📝 Submit Your Manuscript 📘 Author Guidelines 💰 Publication Charges 

✅ No Submission Fee •  📜 Free Publication Certificate • 🌍 Global Visibility

⭐ Popular Pages


  • 🌍 International Journal
  • 🌐 Open Access Journal
  • 👨‍⚖️ Peer-Reviewed Journal
  • 💰 Low APC Journal
  • 🚀 Fast Publication Journal
  • ⚡ Fast-Track Peer-Review
  • 🔗 Crossref DOI Journal
  • 📖 Refereed Journal
  • 📈 High Impact Journal
  • 🧬 International Biology Journal
  • 💊 International Pharmacy Journal
  • 📝 Publish Research Paper

✍️ Author Resources


  • 📝 Publish Research Paper
  • 📖 Author Guidelines
  • 🎯 Aims and Scope
  • 💳 Article Processing Charges
  • 📤 Submit Manuscript
  • 📄 Cover Letter
  • ✍️ Author Declaration Form
  • 📄Track Manuscript Status
  • 📜 Get Publication Certificate
  • 📚 Journal Past Issue Archive
  • 🔎 Journal Indexing

⚖️ Journal Policies


  • ⚖️ Publication Ethics
  • 🛡️ Plagiarism Policy
  • 👨‍🔬 Peer Review Policy
  • 👨‍⚖️ Peer Review Process
  • 📖 Open Access Publishing
  • 📜 Copyright & Licensing
  • 🔗Author Self-Archiving Policy
  • 👥 Authorship Policy
  • 📊 Data Sharing Policy
  • 🤖 AI Usage Policy

Copyright © 2026 GSC Biological and Pharmaceutical Sciences - All rights reserved

Developed & Designed by VS Infosolution